Literature DB >> 23050999

Chinese psychiatrists views on global features of CCMD-III, ICD-10 and DSM-IV.

Yi-Zhuang Zou1, Jie-Feng Cui, Biao Han, Ai-Li Ma, Man-Ying Li, Hong-Zhen Fan.   

Abstract

OBJECTIVE: To survey psychiatrists' opinions about psychiatric classification in China, and provide information and suggestions for developing a new version of classificatory system.
METHOD: The questionnaire about psychiatry classification written by Professor Graham Mellsop, New Zealand, was translated and modified into Chinese. An anonymous field survey of 380 psychiatry professionals was undertaken in Beijing.
RESULTS: A total of 181 questionnaires were eligible for analysis. The Chinese Classification of Mental Disorders version 3 (CCMD-III) is the most commonly used in China (63.8%), then ICD-10 (28.5%) and DSM-IV (7.7%). Half of the respondents (53.0%) agreed that the most important diagnostic classification is for communication among physicians, and then for communication between physician and patient (21.0%). Most professionals (90.0%) agree that classification should include less than 100 diagnostic options. Disagreement presents on cross-culture application of the ICD-10 and DSM-III: 75.1% professionals agreed that they are "useful and reliable regardless of patient ethnicity and culture", while 46.8% found "sometimes difficult to apply across cultures", and 35.8% thought classification is "over-embedded in European cultural concepts and values".
CONCLUSION: There is a strong trend of convergence and unification of China's diagnostic standards with international standards inevitable. A classification that is less complicated and confused, easy-to-communicate and understand and cross-cultural/nation applicable is expected by most Chinese psychiatrists. Such classification should also be reflective of the advances in understanding of aetiology of disorders and helpful in clinical management.
Copyright © 2008. Published by Elsevier B.V.

Entities:  

Year:  2008        PMID: 23050999     DOI: 10.1016/j.ajp.2008.09.007

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  6 in total

1.  Current state and recent developments of child psychiatry in China.

Authors:  Yi Zheng; Xixi Zheng
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2015-05-13       Impact factor: 3.033

2.  Clinical Trial Research on Mongolian Medical Warm Acupuncture in Treating Insomnia.

Authors:  Agula Bo; Lengge Si; Yuehong Wang; Lan Xiu; Rihan Wu; Yutang Li; Rigenjiya Mu; Latai Ga; Mei Miao; Fu Shuang; Yunhua Wu; Qiu Jin; Suocai Tong; Gerile Wuyun; Wurihan Guan; Rigen Mo; Sileng Hu; Lixia Zhang; Rui Peng; Lidao Bao
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-05       Impact factor: 2.629

3.  Efficacy and mechanism of acupuncture for ischemic poststroke depression: Study protocol for a multicenter single-blinded randomized sham-controlled trial.

Authors:  Hai Lu; Menghan Li; Bo Zhang; Xuesong Ren; Lina Meng; Weijing Bai; Li Wang; Zhenzhen Wang; Shaojie Ding; Yuanyuan Gan; Zhilong Zhang; Peifang Li; Linpeng Wang; Zhihong Meng; Hong Zhao; Fei Wang; Chunhong Zhang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

4.  Effectiveness and safety of manual acupuncture therapy in patients with post-stroke depression: a protocol for a systematic review and meta-analysis.

Authors:  Wei Liu; Chang Rao; Qi Zhao; Yuzheng Du; Xi Nan; Zefang Li; Chunsheng Yin
Journal:  BMJ Open       Date:  2021-12-10       Impact factor: 2.692

5.  Application value of selected serum indicators in the differential diagnosis of geriatric depression and transient depressive state.

Authors:  Yuhao Xu; Shun Yao; Hong Wei; Xiaolan Zhu; Ming Yu; Yuefeng Li
Journal:  Neuropsychiatr Dis Treat       Date:  2018-02-08       Impact factor: 2.570

6.  The efficacy of Tai Chi for depression: A protocol for systematic review and meta-analysis.

Authors:  Guojian He; Xiucai Zhang; Ting Yan; Jiayi Wang; Qi Li; Tianyu Liu; Youn-Poong Oh
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.